NGM Biopharmaceuticals wants to be the next billion-dollar biotech on Wall Street, and so it’s moving forward with an IPO that offers a springtime referendum on investor sentiment.
Back in September, South San Francisco-based NGM filed paperwork to go public but fell silent as biotech indices tumbled in the fourth quarter. Now, apparently pleased with the state of the market, NGM has revived those plans and is pitching an offering that would value the company at about $1.1 billion.
Whether NGM can get that valuation will be interesting to watch. On the one hand, NGM’s most advanced therapy is meant to treat NASH, a liver disease whose prevalence has made it a popular target for drug companies predicting a blockbuster opportunity. On the other hand, it uses a biological pathway that has in the past been linked to liver cancer in rats, an association that led to an FDA-imposed clinical hold back in 2014.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect